Gene therapy maker bluebird to restate 2022 financial statements

bluebird bio

26/03/2024 11:06

March 26 (Reuters) - Gene therapy maker bluebird bio
 BLUE.O  said on Tuesday it plans to restate its financial
statements for 2022 and for each of the first three quarters of
2022 and 2023 following accounting errors.
    The company has also identified "material weakness in its
internal control over financial reporting", it said.

 (Reporting by Leroy Leo in Bengaluru; Editing by Shounak
Dasgupta)
 ((Leroy.Dsouza@thomsonreuters.com; https://twitter.com/LeroyLeo7))